baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Galapagos NV/ BE0003818359 /

26/02/2024 09:12:02	Chg. -	Volume	Bid09:00:23	Ask09:00:23	Market Capitalization	Dividend Y.	P/E Ratio
33.17EUR	-	175 Turnover: 5,803.95	-Bid Size: -	-Ask Size: -	1.76 bill.EUR	-	8.31

GlobeNewswire 04/04 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...

GlobeNewswire 28/03 Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

GlobeNewswire 26/03 Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

GlobeNewswire 22/02 Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Cl...

GlobeNewswire 22/02 Galapagos announces full year 2023 results and outlook for 2024

GlobeNewswire 15/02 Galapagos presents at EBMT-EHA annual meeting 2024

GlobeNewswire 05/02 NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

GlobeNewswire 31/01 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

GlobeNewswire 04/01 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...

GlobeNewswire 03/01 Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule dru...

GlobeNewswire 02/01 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

GlobeNewswire 22/12/2023 Oceana Finds China’s Fishing Fleet Swarms Galápagos, then Disappears from Sight

GlobeNewswire 19/12/2023 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...

GlobeNewswire 09/12/2023 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...

GlobeNewswire 07/12/2023 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...

GlobeNewswire 02/11/2023 Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies fo...

GlobeNewswire 01/11/2023 SweetWater Brewing Company Launches Special-Edition 420 IPA in Partnership With the Georgia Aquarium...

GlobeNewswire 30/10/2023 Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business t...

GlobeNewswire 19/09/2023 Galapagos appoints Simon Sturge to its Board of Directors

GlobeNewswire 28/08/2023 Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with...

GlobeNewswire 28/03/2022 Jyseleca® approved in Japan for ulcerative colitis

GlobeNewswire 24/03/2022 Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholde...

GlobeNewswire 24/03/2022 Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings

GlobeNewswire 18/03/2022 Galapagos increases share capital through subscription right exercises

GlobeNewswire 24/02/2022 Galapagos 2021 results set stage for future growth

Galapagos NV/ BE0003818359 /

If you wish to receive reply to your feedback, please provide your email address.